Compare Sanofi SA (SNY) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Trip.com Group Ltd — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Trip.com Group Ltd trades at $43.83 (market cap $28.12B). The key difference: Sanofi SA is far larger — about 3.7× Trip.com Group Ltd's market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| SNY | TCOM | |
|---|---|---|
Market Cap | $104.83B | $28.12B |
Sector | Health | Consumer Cyclical |
52-Week High | $52.34 | $78.96 |
52-Week Low | $41.33 | $39.84 |
Enterprise Value | $121.32B | $20.82B |
Dividend Yield | 5.5% | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Trip.com Group (TCOM) trades at $43.65, up 2.83% with strong fundamentals including a 6.64 P/E ratio and 48.65% net margin. Recent Q1 2026 earnings missed expectations at $0.83 per share versus $0.85 expected, though revenue grew 17% year-over-year. Technical indicators show a bullish overall signal with resistance near $45, while news highlights institutional buying and regulatory scrutiny concerns.
The outlook remains positive with a $56.72 analyst price target implying 30% upside, supported by robust cash flow and expanding profitability. Key risks include Q2 revenue guidance of 3%-8% growth lagging expectations and ongoing antitrust investigations in China that could pressure margins near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
